Newomics Inc. and Bruker Corporation have announced collaborations on a novel LC-MS platform for drug discovery in the pharma/biopharma industry as well as research institutions. The two companies agreed on co-marketing Newomics’s Microflow-nanospray electrospray ionisation (MnESI) product line with Bruker’s maxis II and timsTOF Pro 2 mass spectrometers.
“We are excited to expand our successful collaborations with Bruker”, said Daojing Wang, Newomics Founder and CEO. “Our M3 emitter is the first commercial multinozzle emitter for mass spectrometry. The new MnESI source directly addresses several key pain points in mass spectrometry analysis of native proteins, protein complexes and oligonucleotides, and opens up new opportunities for biopharmaceutical and clinical research and development.”
